Whoever missed the ozempic or overall GLP-1 wave the first time, which led to large gains in NVO stock, now has a second chance to get in due to the stock's downturn. In February, I wrote a Novo Nordisk (I objectively search for undervalued stocks of any size across a wide variety of industries using quantitative methods that I've thoroughly backtested for success. I believe the numbers are more important than the story (most of the time), as they tend to paint a more realistic picture of the company’s pros ...

they're going to lose the listing either way. >> Yeah. But potentially good news for the US and the administration and other health care news.Some big changes are underway in the weight loss space. Starting today, CVS health will prioritize Novo Nordisk's Wegovy as the pharmacy's preferred GLP one drug and dropping Zepp from its list of covered drugs and a potential blow to Eli Lilly. Joining us now is Mizuho Healthcare strategist Jared Holt.Why does it have to be one or the other. Jared. >> Hey, Sara.Thank ...

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Hims & Hers and cert ...

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during a defined class period [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025 [2]. - Investors are encouraged to contact the Schall Law Firm before August 25, 2025, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Hims & Hers made false and misleading statements regarding its marketing practices, particularly in relation to the promotion of products that could jeopardize patient safety [4]. - The company faced the risk of having its partnership with Novo Nordisk terminated due to these deceptive marketing activities [4]. - The misleading public statements resulted in financial damages to investors once the truth about the company's practices was revealed [4].

RADNOR, Pa., June 30, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25 ...

Core Viewpoint - Two securities class action lawsuits have been filed against Hims & Hers Health, Inc. and certain executives, representing investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3] Group 1: Lawsuits and Allegations - The lawsuits allege that Hims & Hers made false and misleading statements and failed to disclose critical information to investors, particularly regarding the deceptive promotion and sale of knockoff versions of the weight loss drug Wegovy® [4] - The lawsuits were prompted by Novo Nordisk's announcement of terminating its collaboration with Hims & Hers due to concerns over "illegal mass compounding and deceptive marketing," which led to a 30% drop in Hims & Hers' share price [2][5] Group 2: Investor Impact and Legal Proceedings - Investors learned of the issues on June 23, 2025, when Novo Nordisk publicly stated that Hims & Hers had not adhered to legal standards, jeopardizing patient safety and the collaboration [5] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [3][6]

Market Competition - Novo Nordisk and Eli Lilly, dominating the global obesity drug market, encounter their first serious rival in China [1]

Summary of China GLP-1 Market Update Industry Overview - **Industry**: China Pharma and Biotech, specifically focusing on the GLP-1 market - **Key Products**: Semaglutide (Ozempic, Wegovy) and Tirzepatide Core Insights 1. **Sales Performance**: - Semaglutide sales in China increased by **110% QoQ** in 1Q25 after a **49% QoQ** decline in 4Q24, indicating easing supply constraints. However, YoY growth has slowed from over **100%** to **19%** [1][6][7] - The Chinese market contributes only **2-4%** of global GLP-1 sales, significantly lagging behind the US market, which accounts for **70-80%** [6][15] 2. **Pricing Trends**: - A **5-7%** price decline for Semaglutide has resumed in 2025 after stabilization in late 2024. Hospital pricing fell by **7-8% QoQ** in 1Q25 [2][23][33] - Tirzepatide is priced **2-3 times** higher than Semaglutide, with monthly costs ranging from **CNY 3,000 to CNY 4,000** [26][38] 3. **Market Segmentation**: - The GLP-1 market in China is segregated into hospital pricing (lower, NRDL-covered) and retail pricing (higher, not covered by insurance) [22][28] - New GLP-1 drugs like Wegovy and Tirzepatide are expected to remain outside of NRDL coverage, maintaining higher retail prices [22][29] 4. **Competitive Landscape**: - The market is becoming increasingly competitive with **7 domestic players** showing weight loss efficacy over **15%** [3] - United Laboratories has entered an exclusive licensing agreement with Novo Nordisk for UBT251, a new GLP-1 drug, with potential milestone payments up to **CNY 1.8 billion** [49] 5. **Clinical Trials and Efficacy**: - Recent trials show promising results for various GLP-1 drugs, with weight loss efficacy ranging from **9.5% to 19.8%** in different studies [50][51] - Notable results include Raynovent's RAY1225 showing **15.1%** weight loss in a Phase 2 trial and BrightGene's BGM0504 reporting up to **19.8%** weight loss [50] Additional Important Insights - **Supply Constraints**: Despite recent improvements in supply, Tirzepatide continues to face shortages, affecting its availability in online pharmacies [29][25] - **Long-term Pricing Outlook**: The expectation is that domestic supply of new GLP-1 drugs will drive prices down significantly in the long term, potentially to **CNY 300/month** [2] - **Investment Ratings**: Companies like Hansoh, Innovent, and Jiangsu Hengrui are rated as Outperform, while CSPC is rated as Market-Perform [5] This summary encapsulates the key points from the conference call regarding the current state and future outlook of the GLP-1 market in China, highlighting both opportunities and challenges within the industry.

Core Insights - Biotechnology stocks, with exceptions like Novo Nordisk and Eli Lilly, faced challenges in attracting investment capital in 2024 due to a high interest rate environment [1] - The FDA's cautious approach to drug approvals, particularly in breakthrough areas like gene therapy, has impacted large-cap drug companies [2] - The biotech industry is leveraging AI to enhance efficiencies and accelerate drug development, particularly in precision medicine [3] Company-Specific Insights - **Iovance Biotherapeutics**: Received FDA approval for Amtagvi, the first TIL therapy for solid tumors, transitioning from clinical stage to revenue generation. However, the stock is down 75.8% in 2025, with concerns over slow sales and cash burn projected at $300 million for the year [5][6][8] - **Neurocrine Biosciences**: Projecting revenue between $2.5 billion and $2.6 billion in 2025 from its Ingrezza therapy. The approval of Crenessity for congenital adrenal hyperplasia could boost revenue significantly, with peak U.S. sales estimated at $800 million to $1 billion [9][10][11] - **Viking Therapeutics**: Stock is down 33% as it awaits Phase 2 results for its GLP-1 candidate VK2735. The company faces competition from Eli Lilly and has significant short interest, but claims of durable weight loss could provide a competitive edge [13][14][15]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. regarding potential securities fraud or unlawful business practices [1] - Novo Nordisk has discontinued its partnership with Hims & Hers due to non-compliance with legal regulations concerning the sale of compounded drugs, which has raised patient safety concerns [3] - Following the announcement of the partnership termination, Hims & Hers' stock price dropped by $22.24, or 34.63%, closing at $41.98 per share [3] Company Overview - Hims & Hers Health, Inc. is publicly traded on the NYSE under the ticker symbol HIMS [1] - The company has faced scrutiny regarding its business practices, particularly in relation to the sale of compounded drugs [3] Legal and Regulatory Context - The investigation by Pomerantz LLP suggests potential legal challenges for Hims & Hers, which may impact investor confidence [1] - Novo Nordisk's decision to end the partnership highlights regulatory compliance issues that could affect Hims & Hers' operations and reputation [3]